search
Back to results

Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD

Primary Purpose

Pulmonary Thromboembolisms, Pulmonary Embolism

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Recombinant tissue plasminogen activator (rt-PA)
Low Molecular Weight Heparin
Sponsored by
Beijing Chao Yang Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Thromboembolisms focused on measuring pulmonary embolism, right ventricular dysfunction, Thrombolysis, Heparin

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 18 y≤Age≤75y
  2. Acute PE (first symptoms occurred 14 d or less before randomization) confirmed by lung scan, or a positive computed tomographic pulmonary angiogram, or a positive selective pulmonary angiogram
  3. Hemodynamic stability, diastolic pressure>90mmHg.

  4. RV dysfunction confirmed by echocardiography (≥1 criterion), except left-side heart disease, congenital heart disease and mitral valve disease.

    • Increase of the right ventricle showed presented with RV end-diastolic anteroposterior diameter >25 mm, Right/left ventricular end-diastolic diameter >1 (apical or subcostal 4-chamber view) or Right/left ventricular end-diastolic anteroposterior diameter >0.5
    • Hypokinesis of RV-free wall (range of motion less than 5 mm)
    • Tricuspid regurgitation pressure >30mmHg

Exclusion Criteria:

  1. RV anterior wall thickness > 5mm confirmed by echocardiography
  2. Active internal bleeding and spontaneous intracranial hemorrhage in preceding 6 months
  3. Major surgery, organ biopsy or non-compressible punctures within 2 weeks
  4. Ischemic stroke occurred within 2 months
  5. Gastrointestinal bleeding within 10 days
  6. Severe trauma occurred within15 days
  7. Neurosurgery or eye surgery within 1 months
  8. Severe hypertension difficult to control (systolic blood pressure>180mmHg or diastolic blood pressure>110mmHg)
  9. Cardiopulmonary resuscitation
  10. Platelet count less than 100×109 / L
  11. Pregnancy, or within 2 week post partum
  12. Infective endocarditis; left atrial thrombus; aneurysm
  13. Serious liver and kidney dysfunction
  14. Diabetic hemorrhagic retinopathy
  15. Suffering with bleeding disorders
  16. Chronic thromboembolic pulmonary hypertension
  17. Moderate to severe chronic obstructive pulmonary disease (COPD).

Sites / Locations

  • Beijing Daxing People's HospitalRecruiting
  • Beijing Fuwai HospitalRecruiting
  • Beijing Hospital, Ministry of Health
  • Beijing Chao Yang HospialRecruiting
  • The Third Affiliated Hospital of Zhongshan University in GuangzhouRecruiting
  • The First Affiliated Hospital of Zhongshan University in GuangzhouRecruiting
  • The Guangxi Zhuang Autonomous Region people's HospitalRecruiting
  • Guangzhou Shenzhen People's HospitalRecruiting
  • Affiliated Hospital of Chengde Medical CollegeRecruiting
  • The first hospital of Handan city Hebei ProvinceRecruiting
  • Hebei Hengshui international Heping HospitalRecruiting
  • Hebei Affiliated Hospital of North China Coal Medical UniversityRecruiting
  • Hebei Medical University Second HospitalRecruiting
  • No.2 Affiliated Hospital of Harbin Medical UniversityRecruiting
  • The Third Affiliated Hospital of Inner Mongolia Medical CollegeRecruiting
  • Hospital of Inner Mongolia Autonomous RegionRecruiting
  • Anshan Iron and Steel Company General HospitalRecruiting
  • The first hospital of Dalian Medical UniversityRecruiting
  • Liaoning General Hospital of Shenyang Military RegionRecruiting
  • Shenyang Medical College affiliated Fengtian HospitalRecruiting
  • Affiliated Hospital of Ningxia Medical UniversityRecruiting
  • Shandong Jining Medical University Affiliated HospitalRecruiting
  • Shandong Medical College Affiliated Hospital of Qiingdao UniversityRecruiting
  • Shandong Yantai city Yantai Mountain hospitalRecruiting
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong UniversityRecruiting
  • Second Military Medical University Changhai HospitalRecruiting
  • Zhongshan Hospital Affiliated to Shanghai Fudan UniversityRecruiting
  • Shanxi Medical University Second HospitalRecruiting
  • The first hospital of Shanxi Medical UniversityRecruiting
  • The Fourth Military Medical University, Xijing HospitalRecruiting
  • Sichuan University, West China HospitalRecruiting
  • The first hospital of Xinjiang Medical UniversityRecruiting
  • The Xinjiang Uygur Autonomous Region people's HospitalRecruiting
  • Zhejiang Sir Run Run Shaw HospitalRecruiting
  • The First Affiliated Hospital of Wenzhou Medical College in ZhejiangRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Low dose (50mg/2h) rt-PA plus LMWH

LMWH

Arm Description

Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen

Low molecular weight heparin

Outcomes

Primary Outcome Measures

the composite end point of death from any cause or treatment failure,recurrence of VTE
improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs
serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes
clinical relevant non-major bleedings

Secondary Outcome Measures

the composite end point of death from any cause or treatment failure,recurrence of VTE
improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs
serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes
clinical relevant non-major bleedings

Full Information

First Posted
February 9, 2012
Last Updated
February 11, 2012
Sponsor
Beijing Chao Yang Hospital
Collaborators
Ministry of Science and Technology of the People´s Republic of China
search

1. Study Identification

Unique Protocol Identification Number
NCT01531829
Brief Title
Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
Official Title
Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized，Multi-Center，Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Unknown status
Study Start Date
July 2009 (undefined)
Primary Completion Date
July 2012 (Anticipated)
Study Completion Date
December 2012 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Chao Yang Hospital
Collaborators
Ministry of Science and Technology of the People´s Republic of China

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In selected patients with acute pulmonary embolism(PE), low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) regimen had been reported to have less bleeding tendency than the FDA-approved rt-PA 100mg/2h regimen 100mg/2h regimen (3% vs.10%), it is worthwhile to reveal whether low dose rt-PA plus low molecular weight heparin (LMWH) can rapidly reverses RV pressure overload in PE, but not increase bleeding and other adverse events. The aim of the study is to compare thrombolytic treatment with LMWH in patients with acute normotensive PE with right ventricular dysfunction(RVD).
Detailed Description
In acute pulmonary embolism (PE), normotensive patients with acute RV dysfunction on echocardiography or computed tomography and with myocardial troponin elevation may have an adverse outcome. Thrombolysis rapidly reverses RV pressure overload in PE, but it increases the possibility of bleeding and it remains unclear whether it may improve the early or long-term clinical outcome of these selected normotensive patients. In our previous study, we found that low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) regimen had less bleeding tendency than the 100mg/2h regimen (3% vs.10%), it is worthwhile to reveal whether low dose rt-PA plus Low Molecular Weight Heparin (LMWH) can rapidly reverses RV pressure overload in PE, but not increase bleeding and other adverse events. In this prospective, multicenter, randomized, control study, we compare low dose rt-PA plus LMWH vs. LMWH alone in acute normotensive pulmonary embolism patients with RV dysfunction. The primary efficacy outcome is the composite of death from any cause or treatment failure, improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs within 7 days of randomization. Second efficacy outcome is the recurrence of pulmonary embolism and deep venous thrombosis. Safety outcomes include serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes, also include mild bleeding. In addition, 90-day clinical and echocardiographic follow-up will be performed, the recurrence of pulmonary embolism and deep venous thrombosis will be recorded. The study is expected to enroll approximately 460 patients. By determining the benefits vs risks of Low dose rt-PA plus LMWH compared with LMWH alone for the treatment in submassive or intermediate-risk PE, this trial is expected to reveal the worth of Low dose rt-PA plus LMWH treatment and what kind of PE patients are suitable for thrombolysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Thromboembolisms, Pulmonary Embolism
Keywords
pulmonary embolism, right ventricular dysfunction, Thrombolysis, Heparin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
460 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Low dose (50mg/2h) rt-PA plus LMWH
Arm Type
Experimental
Arm Description
Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
Arm Title
LMWH
Arm Type
Active Comparator
Arm Description
Low molecular weight heparin
Intervention Type
Drug
Intervention Name(s)
Recombinant tissue plasminogen activator (rt-PA)
Other Intervention Name(s)
rt-PA
Intervention Description
Low dose (50mg/2h) rt-PA plus LMWH
Intervention Type
Drug
Intervention Name(s)
Low Molecular Weight Heparin
Other Intervention Name(s)
Nadroparin
Intervention Description
0.1ml/10kg,q12h,5-7 days
Primary Outcome Measure Information:
Title
the composite end point of death from any cause or treatment failure,recurrence of VTE
Time Frame
7 days
Title
improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs
Time Frame
7 days
Title
serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes
Time Frame
7 days
Title
clinical relevant non-major bleedings
Time Frame
7 days
Secondary Outcome Measure Information:
Title
the composite end point of death from any cause or treatment failure,recurrence of VTE
Time Frame
3 months and 6 months
Title
improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs
Time Frame
3 months and 6 months
Title
serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes
Time Frame
3 months and 6 months
Title
clinical relevant non-major bleedings
Time Frame
3 months and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 y≤Age≤75y Acute PE (first symptoms occurred 14 d or less before randomization) confirmed by lung scan, or a positive computed tomographic pulmonary angiogram, or a positive selective pulmonary angiogram Hemodynamic stability, diastolic pressure>90mmHg. RV dysfunction confirmed by echocardiography (≥1 criterion), except left-side heart disease, congenital heart disease and mitral valve disease. Increase of the right ventricle showed presented with RV end-diastolic anteroposterior diameter >25 mm, Right/left ventricular end-diastolic diameter >1 (apical or subcostal 4-chamber view) or Right/left ventricular end-diastolic anteroposterior diameter >0.5 Hypokinesis of RV-free wall (range of motion less than 5 mm) Tricuspid regurgitation pressure >30mmHg Exclusion Criteria: RV anterior wall thickness > 5mm confirmed by echocardiography Active internal bleeding and spontaneous intracranial hemorrhage in preceding 6 months Major surgery, organ biopsy or non-compressible punctures within 2 weeks Ischemic stroke occurred within 2 months Gastrointestinal bleeding within 10 days Severe trauma occurred within15 days Neurosurgery or eye surgery within 1 months Severe hypertension difficult to control (systolic blood pressure>180mmHg or diastolic blood pressure>110mmHg) Cardiopulmonary resuscitation Platelet count less than 100×109 / L Pregnancy, or within 2 week post partum Infective endocarditis; left atrial thrombus; aneurysm Serious liver and kidney dysfunction Diabetic hemorrhagic retinopathy Suffering with bleeding disorders Chronic thromboembolic pulmonary hypertension Moderate to severe chronic obstructive pulmonary disease (COPD).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chen Wang, PhD,MD
Phone
8610-85231893
Email
cyh-birm@263.net
First Name & Middle Initial & Last Name or Official Title & Degree
Tuguang Kuang, PhD,MD
Phone
8610-85231451
Email
ktg2004@sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chen Wang, PhD,MD
Organizational Affiliation
Beijing Chao Yang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beijing Daxing People's Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yongxiang Zhang, MD
First Name & Middle Initial & Last Name & Degree
Yongxiang Zhang, MD
Facility Name
Beijing Fuwai Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhihong Liu, MD
First Name & Middle Initial & Last Name & Degree
Zhihong Liu, MD
Facility Name
Beijing Hospital, Ministry of Health
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Baomin Fang, MD
First Name & Middle Initial & Last Name & Degree
Baoming Fang, MD
Facility Name
Beijing Chao Yang Hospial
City
Bejing
State/Province
Beijing
ZIP/Postal Code
100020
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuanhua Yang, PhD,MD
Phone
8610-65060167
Email
yyh1031@sina.com
First Name & Middle Initial & Last Name & Degree
Chen Wang, PhD,MD
First Name & Middle Initial & Last Name & Degree
Yuanhua Yang, PhD,MD
Facility Name
The Third Affiliated Hospital of Zhongshan University in Guangzhou
City
Guang Zhou
State/Province
GUang Dong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
yulin Zhou, MD
First Name & Middle Initial & Last Name & Degree
Tiantuo Zhang, MD
Facility Name
The First Affiliated Hospital of Zhongshan University in Guangzhou
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mian Zeng, MD
First Name & Middle Initial & Last Name & Degree
Canmao Xie, MD
Facility Name
The Guangxi Zhuang Autonomous Region people's Hospital
City
Nan ning
State/Province
Guangxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
shengze Long, MD
First Name & Middle Initial & Last Name & Degree
Zhiqiang Qing, PhD,MD
Facility Name
Guangzhou Shenzhen People's Hospital
City
Shenzhen
State/Province
Guangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chen Qiu, MD
First Name & Middle Initial & Last Name & Degree
Chen Qiu, MD
Facility Name
Affiliated Hospital of Chengde Medical College
City
Chengde
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guifang Pang, MD
First Name & Middle Initial & Last Name & Degree
Qing Zhang, MD
Facility Name
The first hospital of Handan city Hebei Province
City
Handan
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinghui Ye, MD
First Name & Middle Initial & Last Name & Degree
Jinghui Ye, MD
Facility Name
Hebei Hengshui international Heping Hospital
City
Hengshui
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhaobo Cui, MD
First Name & Middle Initial & Last Name & Degree
Zhaobo Cui, MD
Facility Name
Hebei Affiliated Hospital of North China Coal Medical University
City
Shijiazhuang
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Baibing Liu, MD
First Name & Middle Initial & Last Name & Degree
Hongyang Wang, MD
Facility Name
Hebei Medical University Second Hospital
City
Shijiazhuang
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yadong Yuan, MD
First Name & Middle Initial & Last Name & Degree
Yadong Yuan, MD
Facility Name
No.2 Affiliated Hospital of Harbin Medical University
City
Harbin
State/Province
Heilongjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hong Chen, MD
First Name & Middle Initial & Last Name & Degree
Hong Chen, MD
Facility Name
The Third Affiliated Hospital of Inner Mongolia Medical College
City
Baotou
State/Province
Inner Mongolia
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ling Wang, MD
First Name & Middle Initial & Last Name & Degree
Jingping Yang, MD
Facility Name
Hospital of Inner Mongolia Autonomous Region
City
Hohhot
State/Province
Inner Mongolia
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Weilie Wang, MD
First Name & Middle Initial & Last Name & Degree
Wenting Zhang, MD
Facility Name
Anshan Iron and Steel Company General Hospital
City
Anshan
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hongyu Zhou, MD
First Name & Middle Initial & Last Name & Degree
Hongyu Zhou, MD
Facility Name
The first hospital of Dalian Medical University
City
Dalian
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yingqun Ji, MD
First Name & Middle Initial & Last Name & Degree
Zhonghe Zhang, MD
Facility Name
Liaoning General Hospital of Shenyang Military Region
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liang Shi, MD
First Name & Middle Initial & Last Name & Degree
Zhuang Ma, MD
Facility Name
Shenyang Medical College affiliated Fengtian Hospital
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shuyue Xia, MD
First Name & Middle Initial & Last Name & Degree
Shuyue Xia, MD
Facility Name
Affiliated Hospital of Ningxia Medical University
City
Yinchuan
State/Province
Ningxia
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zheng Yang, MD
First Name & Middle Initial & Last Name & Degree
Jin Zhang, MD
Facility Name
Shandong Jining Medical University Affiliated Hospital
City
Jining
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luning Jiang, MD
First Name & Middle Initial & Last Name & Degree
Luning Jiang, MD
Facility Name
Shandong Medical College Affiliated Hospital of Qiingdao University
City
Qingdao
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Tong, MD
First Name & Middle Initial & Last Name & Degree
Zhaozhong Cheng, MD
Facility Name
Shandong Yantai city Yantai Mountain hospital
City
Yantai
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lijun Kang, MD
First Name & Middle Initial & Last Name & Degree
Shudong Zhang, MD
Facility Name
Ruijin Hospital Affiliated to Shanghai Jiao Tong University
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guochao Shi, MD
First Name & Middle Initial & Last Name & Degree
Shaoguang Huang, MD
Facility Name
Second Military Medical University Changhai Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei Zhang, MD
First Name & Middle Initial & Last Name & Degree
Qiang Li, MD
Facility Name
Zhongshan Hospital Affiliated to Shanghai Fudan University
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinjun Jiang, MD
First Name & Middle Initial & Last Name & Degree
Chunxue Bai, PhD,MD
Facility Name
Shanxi Medical University Second Hospital
City
Taiyuan
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xu Wang, MD
First Name & Middle Initial & Last Name & Degree
Zhuola Liu, MD
Facility Name
The first hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaoyun Hu, MD
First Name & Middle Initial & Last Name & Degree
Yongcheng Du, MD
Facility Name
The Fourth Military Medical University, Xijing Hospital
City
Xi'an
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shengqing Li, PhD, MD
First Name & Middle Initial & Last Name & Degree
Changgui Wu, MD
Facility Name
Sichuan University, West China Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qun Yi, MD
First Name & Middle Initial & Last Name & Degree
Qun Yi, MD
Facility Name
The first hospital of Xinjiang Medical University
City
Urumqi
State/Province
Xinjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zaiyi Wang, MD
First Name & Middle Initial & Last Name & Degree
Zaiyi Wang, MD
Facility Name
The Xinjiang Uygur Autonomous Region people's Hospital
City
Urumqi
State/Province
Xinjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Chen, MD
First Name & Middle Initial & Last Name & Degree
Xiaohong Yang, MD
Facility Name
Zhejiang Sir Run Run Shaw Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guofeng Ma, MD
First Name & Middle Initial & Last Name & Degree
Kejing Ying, MD
Facility Name
The First Affiliated Hospital of Wenzhou Medical College in Zhejiang
City
Wenzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yupeng Xie, MD
First Name & Middle Initial & Last Name & Degree
Liangxing Wang, MD

12. IPD Sharing Statement

Learn more about this trial

Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD

We'll reach out to this number within 24 hrs